Law Office of Brodsky & Smith, LLC Announces Investigation of SeraCare Life Sciences, Inc.
15 Febrero 2012 - 11:41AM
Business Wire
Law office of Brodsky & Smith, LLC announces that it is
investigating potential claims against the Board of Directors of
SeraCare Life Sciences, Inc. (“SeraCare” or the “Company”) (Nasdaq:
SRLS) relating to the proposed acquisition by Linden Capital
Partners (“Linden”).
Under the terms of the transaction, SeraCare shareholders would
receive $4.00 in cash for each share of SeraCare stock they own.
The investigation concerns possible breaches of fiduciary duty and
other violations of state law by the Board of Directors of SeraCare
for not acting in the Company’s shareholders' best interests in
connection with the sale process to Linden. The transaction may
undervalue SeraCare as SeraCare stock traded at $5.45 on May 11,
2010 and traded at $4.85 as recently as January 12, 2011. In
addition, an analyst has set a price target of $5.00 for each
SeraCare share.
If you own shares of SeraCare stock and wish to discuss the
legal ramifications of the proposed transaction, or have any
questions, you may e-mail or call the law office of Brodsky &
Smith, LLC who will, without obligation or cost to you, attempt to
answer your questions. You may contact Jason L. Brodsky, Esquire or
Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza,
Suite 602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com, visiting
http://brodsky-smith.com/385-srls-seracare-life-sciences-inc.html,
or by calling toll free 877-LEGAL-90.
Seracare Life Sciences (NASDAQ:SRLS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Seracare Life Sciences (NASDAQ:SRLS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Seracare Life Sciences (MM) (NASDAQ): 0 recent articles
Más de Brodsky & Smith, LLC Artículos de Noticias